Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant human urokinase
- Development stage
- Unknown
- Lead developer
- Nanjing Bio-sci Pharmaceutical
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Recombinant human urokinase (rhUK) is a thrombolytic agent produced using recombinant DNA technology. It is a serine protease that directly converts the zymogen plasminogen into the active enzyme plasmin, which subsequently degrades fibrin clots in the vasculature. Unlike recombinant human pro-urokinase (rhpro-UK), which is a single-chain precursor requiring activation, rhUK is the active two-chain form of the enzyme. It is primarily being investigated in China for the treatment of ST-elevation myocardial infarction (STEMI) to achieve rapid coronary artery recanalization. Clinical development has been significantly led by the Second Hospital Affiliated to Tianjin Medical University, with trials evaluating its efficacy and safety profile in comparison to other thrombolytics such as alteplase and urine-derived urokinase.
- Other names
- recombinant urokinase
02
Targets
PLAUR (Urokinase plasminogen activator receptor)PLG (Plasminogen)
Beyond the preview
Go deeper on recombinant human urokinase.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant human urokinase.